Subclinical activation of lupus nephritis by recombinant human growth hormone.
The effect of growth hormone (GH) on subclinical disease activity in a 15-year-old boy with previously quiescent lupus nephritis and chronic renal failure is described. Institution of supraphysiological doses of GH resulted in a rise in erythrocyte sedimentation rate, decrease in serum complement, rise in anti-DNA antibody titers, and increase in T-cell activation markers, all of which improved following cessation of GH treatment.
Yap
H K
HK
Department of Pediatrics, National University of Singapore, Singapore.
Loke
K Y
KY
Murugasu
B
B
Lee
B W
BW
D001799:Blood Sedimentation; D002648:Child; D003165:Complement System Proteins / Q000378:metabolism; D004247:DNA / Q000276:immunology / Q000378:metabolism; D006130:Growth Disorders / Q000188:drug therapy / Q000209:etiology; D013006:Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D008181:Lupus Nephritis / Q000139:chemically induced* / Q000503:physiopathology; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000187:drug effects; D008297:Male
D013006:Growth Hormone; D003165:Complement System Proteins; D004247:DNA